Search

Stuart D Thomson

from Norwalk, CT
Age ~58
Get Report
Also known as:
Stuart P Thomson, Stuart Thompson, Stewart D Thomson, Stuart D Thomso
Phone and address:
166 Ponus Ave, Norwalk, CT 06850
Related to:
John Jason Thomson, 47
Connected to:
Adena C Thomson, 35Alan G Thomson, 87Albert J Thomson, 32Angela K Thomson, 61Annabel M Thomson, 33Arran E Thomson, 49Ashlee E Thomson, 35Clayton S Thomson, 64Darly K Thomson, 36Darren Thomson, 42

Stuart Thomson Phones & Addresses

  • 166 Ponus Ave, Norwalk, CT 06850
  • Brooklyn, NY
  • 352 86Th St, New York, NY 10001
  • 1303 3Rd St, New York, NY 10021
  • Riverside, CT
  • Anchorage, AK
  • Interlaken, NY

Resumes

Resumes

Stuart Thomson Photo 1

Project Leader

View page
Location:
New York, NY
Industry:
Financial Services
Work:
Sd Thomson
Project Leader - Currently Focusing on Simcorp Dimension
Oppenheimerfunds Dec 2014 - Jul 2018
Program Manager - Investments and Risk Technology
Sapient Global Markets Jul 2012 - Apr 2014
Senior Manager
Ey Jul 2010 - Jul 2012
Senior Manager - Fso
Sd Thomson Jun 2000 - Jul 2010
Consultant
Education:
Hobart College May 2008
Bachelors, Bachelor of Arts Canterbury School
Columbia University
Hobart and William Smith Colleges
Bachelors, Bachelor of Arts, Philosophy, History
Skills:
Financial Services
Hedge Funds
Business Analysis
Fixed Income
Asset Management
Equities
Alternative Investments
Project Management
Portfolio Management
Investment Banking
Capital Markets
Investments
Strategy
Trading
Back Office
Financial Risk
Derivatives
Private Equity
Mutual Funds
Software Development
Geneva
Bloomberg
Asset Managment
Fatca
Portfolio Accounting
Advent Software
Order Management
Operating Models
Business Process
Data Warehousing
Trade Order Management
Data Governance
Data Management
Investment Performance
Swaps
Leadership
Operating Model Design
Investment Performance Measurement
Microsoft Excel
Data Analysis
Business Strategy
Microsoft Powerpoint
Financial Reporting
Agile Methodologies
Agile Project Management
Investment Management Industry
Capital Markets Advisory
Software Project Management
Front To Back Office
Custom Software Development
Certifications:
Pmp
Certified Scrum Product Owner
Certified Scrum Master
Stuart Thomson Photo 2

Stuart Thomson

View page
Stuart Thomson Photo 3

Stuart Thomson

View page
Location:
United States
Stuart Thomson Photo 4

Stuart Thomson

View page
Location:
United States

Business Records

Name / Title
Company / Classification
Phones & Addresses
Stuart Thomson
S.D. THOMSON INC
166 Ponus Ave, Norwalk, CT 06850

Publications

Us Patents

Methods For The Identification Of Agents That Inhibit Mesenchymal-Like Tumor Cells Or Their Formation

View page
US Patent:
7951549, May 31, 2011
Filed:
Mar 6, 2009
Appl. No.:
12/381082
Inventors:
John D. Haley - Sea Cliff NY, US
Stuart Thomson - Port Washington NY, US
Julie Kan - Smithtown NY, US
Salam A. Shaaban - Westborough MA, US
Assignee:
OSI Pharmaceuticals, Inc. - Ardsley NY
International Classification:
G01N 33/574
C12Q 1/02
US Classification:
435 723, 435 29
Abstract:
The present invention provides tumor cell preparations for use as models of the EMT process for use in the identification of anti-cancer agents, wherein said tumor cell preparations comprise cells of the epithelial tumor cell line H358, which are stimulated by receptor ligands to induce EMT, or which have been engineered to inducibly express a protein that stimulates EMT. The present invention also provides methods of identifying potential anti-cancer agents by using such tumor cell preparations to identify agents that inhibit EMT, stimulate MET, or inhibit the growth of mesenchymal-like cells. Such agents should be particularly useful when used in conjunction with other anti-cancer drugs such as EGFR and IGF-1R kinase inhibitors, which appear to be less effective at inhibiting tumor cells that have undergone an EMT.

Biological Markers Predictive Of Anti-Cancer Response To Epidermal Growth Factor Receptor Kinase Inhibitors

View page
US Patent:
8383357, Feb 26, 2013
Filed:
Apr 13, 2007
Appl. No.:
11/787044
Inventors:
John D. Haley - Farmingdale NY, US
Stuart Thomson - Farmingdale NY, US
Filippo Petti - Farmingdale NY, US
Assignee:
OSI Pharmaceuticals, LLC - Farmingdale NY
International Classification:
G01N 33/574
US Classification:
435 723
Abstract:
The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by EGFR kinase inhibitors are also provided.

Biological Markers Predictive Of Anti-Cancer Response To Kinase Inhibitors

View page
US Patent:
20080312260, Dec 18, 2008
Filed:
Apr 14, 2008
Appl. No.:
12/082762
Inventors:
John D. Haley - Sea Cliff NY, US
Stuart Thomson - Port Washington NY, US
International Classification:
A61K 31/517
C12Q 1/02
A61P 35/04
US Classification:
5142664, 435 29
Abstract:
The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Based on the surprising discovery that tumors cells after having undergone an EMT, while being mesenchymal-like, still express characteristics of both epithelial and mesenchymal cells, and that such cells have altered sensitivity to inhibition by receptor protein-tyrosine kinase inhibitors, in that they have become relatively insensitive to EGFR kinase inhibitors, but have frequently acquired sensitivity to inhibitors of other receptor protein-tyrosine kinases such as PDGFR or FGFR, methods have been devised for determining levels of specific epithelial and mesenchymal biomarkers that identify such “hybrid” tumor cells (e.g. determination of co-expression of vimentin and epithelial keratins), and thus predict the tumor's likely sensitivity to inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Improved methods for treating cancer patients with EGFR, PDGFR or FGFR kinase inhibitors that incorporate such methodology are also provided.

Biological Markers Predictive Of Anti-Cancer Response To Kinase Inhibitors

View page
US Patent:
20130210026, Aug 15, 2013
Filed:
Feb 15, 2013
Appl. No.:
13/767972
Inventors:
OSI Pharmaceuticals, LLC - , US
Stuart THOMSON - Port Washington NY, US
International Classification:
G01N 33/68
US Classification:
435 71
Abstract:
The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Based on the surprising discovery that tumors cells after having undergone an EMT, while being mesenchymal-like, still express characteristics of both epithelial and mesenchymal cells, and that such cells have altered sensitivity to inhibition by receptor protein-tyrosine kinase inhibitors, in that they have become relatively insensitive to EGFR kinase inhibitors, but have frequently acquired sensitivity to inhibitors of other receptor protein-tyrosine kinases such as PDGFR or FGFR, methods have been devised for determining levels of specific epithelial and mesenchymal biomarkers that identify such “hybrid” tumor cells (e.g. determination of co-expression of vimentin and epithelial keratins), and thus predict the tumor's likely sensitivity to inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Improved methods for treating cancer patients with EGFR, PDGFR or FGFR kinase inhibitors that incorporate such methodology are also provided.

Biological Markers Predictive Of Anti-Cancer Response To Epidermal Growth Factor Receptor Kinase Inhibitors

View page
US Patent:
20140018375, Jan 16, 2014
Filed:
Feb 22, 2013
Appl. No.:
13/773853
Inventors:
OSI Pharmaceuticals, LLC - , US
Stuart Thomson - Port Washington NY, US
Filippo Petti - Farmingdale NY, US
International Classification:
G01N 33/68
US Classification:
5142664
Abstract:
The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by EGFR kinase inhibitors are also provided.

Isbn (Books And Publications)

The Social Democratic Dilemma: Ideology, Governance and Globalization

View page
Author

Stuart Thomson

ISBN #

0312227868

Dictionary of Labour Quotations

View page
Author

Stuart Thomson

ISBN #

1902301161

Control profile
Stuart D Thomson from Norwalk, CT, age ~58 Get Report